ckd732 and Diabetes-Mellitus--Type-2

Participants were randomised (via a centralised interactive web response system) to placebo, 1.2 or 1.8 mg beloranib s.c. twice weekly for 26 weeks. Participants, investigators and the sponsor were blinded to group assignment. The primary endpoint was the change in weight from baseline to week 26. The trial was terminated early when beloranib development was stopped because of an imbalance of venous thromboembolism events in beloranib-treated individuals vs placebo that became evident during late-stage development of the drug.. MetAP2 inhibitors represent a novel mechanism for producing meaningful weight loss and improvement in HbA. ClinicalTrials.gov NCT02324491 FUNDING: The study was funded by Zafgen, Inc.

Topics: Adolescent; Adult; Aged; Aminopeptidases; Anti-Obesity Agents; Blood Glucose; Body Weight; Cinnamates; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Epoxy Compounds; Female; Glucose; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Male; Metalloendopeptidases; Methionyl Aminopeptidases; Middle Aged; Obesity; Sesquiterpenes; Weight Loss; Young Adult